And note how they mention an "early review" with a positive legacy in Australia.
This is still very early days with respects to market penetration in the states, yet we are already profitable as a stand alone country.
This is why pumping money into sales staff is important - we want to capture as much market as rapidly as possible. Get this into the hands of as many surgeons as possible.
As you can see, these surgeons have published a paper that is better than any advertisement PNV could buy.
Sales are accelerating. But this hasn't begun to snowball yet. In my opinion, it's only a matter of time.
IMO. DYOR.
But what a great article
The Clinicians Speak, page-609
-
- There are more pages in this discussion • 449 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.35 |
Change
-0.080(3.29%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.43 | $2.35 | $1.817M | 764.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4119 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.37 | 8809 | 3 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |